Schrödinger, Inc. (SDGR)
Schrödinger, Inc. operates in the Software - Application industry of the Technology sector, headquartered in New York, NY, US. The stock last traded at $28.85, down 2.04% on the session, giving a market capitalisation of $2.16B. On trailing twelve-month figures it carries a trailing P/E of -38.99, a net margin of -21.0%. Its beta of 1.69 implies it has historically moved more than the broad market.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrödinger, Inc. is most often compared with the following Technology names: